Evidence map›Paper›PMID 38668553›Full record

ArticlePediatric blood & cancer2024

Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda.

Lydia Businge, Marc Hagenimana, Melitah Motlhale, Aude Bardot, Biying Liu, Kathryn Anastos, Philip E Castle, Gad Murenzi, Kimilu Claire, Daniel Sabushimike and 7 more

Abstract read
In one paragraph

Article in Pediatric blood & cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lydia BusingeRwanda Biomedical Centre (RBC), Kigali, Rwanda.ORCID 0000-0003-4621-5747
Marc HagenimanaRwanda Biomedical Centre (RBC), Kigali, Rwanda.
Melitah MotlhaleInternational Agency for Research on Cancer (IARC/WHO), Lyon, France.
Aude BardotInternational Agency for Research on Cancer (IARC/WHO), Lyon, France.
Biying LiuAfrican Cancer Registry Network, Prama House, Oxford, UK.
Kathryn AnastosEinstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.ORCID 0000-0002-0769-6405
Philip E CastleDivisions of Cancer Prevention and Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Gad MurenziEinstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
Kimilu ClaireWorld Health Organization, Geneva, Switzerland.
Daniel SabushimikeRwanda Biomedical Centre (RBC), Kigali, Rwanda.
Callixte CyuzuzoRwanda Biomedical Centre (RBC), Kigali, Rwanda.
Gallican KubwimanaEinstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
Theoneste ManiragabaRwanda Biomedical Centre (RBC), Kigali, Rwanda.
Francois UwinkindiRwanda Biomedical Centre (RBC), Kigali, Rwanda.
Maggie PaczkowskiVital Strategies, New York, USA.
Isabelle SoerjomataramInternational Agency for Research on Cancer (IARC/WHO), Lyon, France.
Donald Maxwell ParkinInternational Agency for Research on Cancer (IARC/WHO), Lyon, France.

Funding

Global Cancer HealthZIACP101237 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CASTLE, PHILIP · 2022 to 2025
$6.6M
Bloomberg Philanthropies Data for Health Initiative 39Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP101237Vital Strategies, Global Grants ProgramWorld Health Organization 001
6 · The paper itself

Abstract

backgroundThe lack of accurate population-based information on childhood cancer stage and survival in low-income countries is a barrier to improving childhood cancer outcomes.

methodsIn this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0-14 diagnosed in 2013-2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non-Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow-ups to calculate 1-, 3- and 5-year observed and relative survival by cancer type and stage at diagnosis.

resultsThe cohort comprised 412 children, of whom 49% (n = 202) died within 5 years of diagnosis. Five-year survival ranged from 28% (95% confidence interval [CI]: 12.5%-45.6%) for BL to 68% (CI: 55%-78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients (n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3-year survival was 70% (95% CI: 45.1%-85.3%) and 11.8% (2.0%-31.2%) for limited and advanced non-HL, respectively (p < .001).

conclusionThis study is only the second to report on stage distribution and stage-specific survival for childhood cancers in sub-Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low-resource setting, and highlights the value of population-based cancer registries in aiding our understanding of the poor outcomes experienced by this population.

Indexed as

NeoplasmsNeoplasm StagingRegistriesAdolescentChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantInfant, NewbornMalePrognosisRwandaSurvival Ratechildhood cancersregistryRwandastagesurvival

Identifiers

PMID38668553
PMCPMC11116036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.